吡非尼酮通过抑制巨噬细胞浸润和TGF-β产生改善小鼠慢性GVHD
该研究在多种慢性移植物抗宿主病(cGVHD)小鼠模型中评估FDA批准用于特发性肺纤维化的药物吡非尼酮的疗效。在主要组织相容性复合体(MHC)完全错配多器官模型伴闭塞性细支气管炎(BO)中,移植后一个月开始吡非尼酮治疗可恢复肺功能并逆转肺纤维化,与减少巨噬细胞浸润和转化生长因子-β(TGF-β)产生相关;在硬皮病样cGVHD模型中,吡非尼酮显著减少皮肤巨噬细胞,但临床改善仅见于一个模型。体外趋化实验显示吡非尼酮损害巨噬细胞向单核细胞趋化蛋白-1(MCP-1)及IL-17A的迁移。数据提示吡非尼酮是改善cGVHD纤维化的潜在治疗药物。
要点
- 移植后一个月开始吡非尼酮可恢复BO模型小鼠肺功能并逆转肺纤维化。
- 吡非尼酮减少肺巨噬细胞浸润和TGF-β产生,并降低脾生发中心B细胞和T滤泡辅助细胞频率。
- 在硬皮病样cGVHD模型中吡非尼酮显著减少皮肤巨噬细胞,但临床改善仅见于一个模型。
核心结论
- 数据提示吡非尼酮是改善cGVHD纤维化的潜在治疗药物。
研究设计与样本
- 在具有不同病理生理的cGVHD小鼠模型中评估吡非尼酮的疗效,包括MHC完全错配多器官系统模型伴BO、次要组织相容性抗原错配模型及MHC单倍体相合硬皮病样cGVHD模型,并进行了体外趋化实验。
主要发现
- 在MHC完全错配多器官系统模型伴BO中,移植后一个月开始吡非尼酮治疗可恢复肺功能并逆转肺纤维化,与减少巨噬细胞浸润和TGF-β产生相关。
- 吡非尼酮降低脾生发中心B细胞和T滤泡辅助细胞频率。
- 在次要组织相容性抗原错配及MHC单倍体相合硬皮病样cGVHD模型中,吡非尼酮显著减少皮肤巨噬细胞,但硬皮病临床改善仅见于一个模型。
- 体外趋化实验显示吡非尼酮损害巨噬细胞向MCP-1及IL-17A的迁移。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus-host disease (cGVHD), resulting in multiorgan fibrosis and diminished function. Fibrosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectively, for which new treatments are needed. We evaluated pirfenidone, a Food and Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its therapeutic effect in cGVHD mouse models with distinct pathophysiology. In a full major histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cell responses that support pathogenic antibody production are required for cGVHD development. Pirfenidone treatment beginning one month post-transplant restored pulmonary function and reversed lung fibrosis, which was associated with reduced macrophage infiltration and transforming growth factor-β production. Pirfenidone dampened splenic germinal center B-cell and T-follicular helper cell frequencies that collaborate to produce antibody. In both a minor histocompatibility antigen-mismatched as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenidone significantly reduced macrophages in the skin, although clinical improvement of scleroderma was only seen in one model. In vitro chemotaxis assays demonstrated that pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL-17A, which has been linked to cGVHD generation. Taken together, our data suggest that pirfenidone is a potential therapeutic agent to ameliorate fibrosis in cGVHD.
引用
- Du J, Paz K, Flynn R, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood. 2017. PMID: 28254742. doi:10.1182/blood-2017-01-758854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。